<DOC>
	<DOCNO>NCT01177228</DOCNO>
	<brief_summary>The main objective study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) multiple dos vedolizumab patient ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Study Vedolizumab Following Multiple Intravenous Doses Patients With Ulcerative Colitis</brief_title>
	<detailed_description>At end study , eligible participant could enroll receive treatment follow-up Study C13004 ( NCT00619489 ) . Participants proceed Study C13004 follow telephone contact 6-month interval 2 year last administration study treatment collect report adverse event , include colectomy , severe infection [ include progressive multifocal leukoencephalopathy ( PML ) ] , dysplasia/cancer .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study . Males nonpregnant , nonlactating female voluntarily able give inform consent All patient must agree use 2 effective form contraception screen end study Negative surveillance colonoscopy within last 6 month indicate standard clinical practice guideline Confirmed active ulcerative colitis ( UC ) Partial Mayo Score 1 7 Disease involvement extend proximal rectum May receive therapeutic dose conventional therapy UC define protocol Patients meet follow exclusion criterion enrol study . Patients require ulcerative colitis ( UC ) surgical intervention surgical intervention anticipate study Patients fail meet laboratory value specify protocol positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist screen period Lowgrade dysplasia , highgrade dysplasia , dysplasiaassociated lesion mass , colorectal cancer Treatment cyclosporine , FK506 ( tacrolimus ) infliximab within 60 day prior study Patients receive follow within 14days prior study : antibiotic treatment irritable bowel syndrome , heparin warfarin , narcotic , tube feeding , define formula diet parenteral alimentation Colostomy , fistulae know fix symptomatic stenosis intestine Immunologic ischemic intestinal condition Toxic megacolon Chronic hepatitis B C human immunodeficiency virus ( HIV ) infection Any vaccination within 30 day prior study drug administration History image abnormality , multiple sclerosis ( MS ) , brain tumor neurodegenerative disease Significantly impair liver renal function Current recent history alcohol dependence Current use illicit drug Active recent serious infection serious underlying disease specify protocol Active psychiatric problem might interfere compliance study Previous exposure MLN0002 Participated investigational study within 30 day prior study drug administration receive treatment investigational monoclonal antibody within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>